PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States
Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
This phase I trial of the replication-intact PfSPZ Challenge vaccine given under CQ cover
will enroll 28 healthy volunteers to receive PfSPZ or placebo, as well as suppressive doses
of chloroquine (CQ)on varying schedules. 10 weeks post 3rd immunization subjects will be
subjected to controlled human malarial infection. The primary objective of this study is to
evaluate the safety and tolerability of escalating doses of Sanaria PfSPZ Challenge
administered by DVI on varying schedules to healthy malaria-naïve adults taking suppressive
doses of CQ (PfSPZ-CVac).
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)